

Zydus expands companion diagnostics portfolio with launch of AI-powered Continuous Glucose Monitor

12 March 2026 | News

Next-gen CGM is paired with AI-powered analytics and a dedicated clinician remote-monitoring dashboard



Zydus Lifesciences has announced its new offering companion diagnostics portfolio. The company will be launching DiasensTM and GlucoLiveTM, next-generation Continuous Glucose Monitoring (CGM) devices that combine artificial intelligence-powered insights, and integrated remote care capabilities.

The CGM system is designed to monitor glucose with an integrated AI layer to provide analytics and enable a closed-loop care ecosystem connecting patients, caregivers, and clinicians in real time.

Zydus has partnered with Digicare Health Solutions (TatvaCareTM), a healthcare technology company to help the patients gain access to its proprietary, integrated care ecosystem GoodFlipTM to provide AI-powered report analysis, personalised diet and exercise coaching, doctor consultations, diagnostic lab booking, and a comprehensive medical record vault - all in a single mobile application.

Despite this burden, most glucose monitoring in India remains episodic - limited to periodic finger-prick tests or laboratory HbA1c checks every three to six months. Existing CGM devices in the Indian market predominantly rely on NFC technology, requiring patients to manually scan the sensor to retrieve readings. This creates gaps in data continuity, delays clinical intervention, and places the burden of vigilance entirely on the patient.

DiasensTM and GlucoLiveTM will enable automatic streaming of glucose readings to the patient's smartphone every three minutes - without manual scanning - ensuring uninterrupted capture, including overnight reading and in emergencies. Through TatvaCareTM's GoodFlipTM app, AI analytics will detect trends, flags hypo-/hyperglycaemic episodes, link fluctuations to food and activity, and generate actionable insights. A clinician dashboard will support remote monitoring, early intervention, and data-driven treatment adjustments.